Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 111 to 120 of 2450 total matches.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 03, 2014 (Issue 1437)
Table 1. Pharmacology
Drug class Soluble guanylate cyclase (sGC) stimulator
Route Oral
Formulation ...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
. Pharmacologic
treatment has included off-label use of timed loop
diuretics and desmopressin.1,2
Table 1 ...
The FDA has approved a sublingual tablet (Nocdurna –
Ferring) and a nasal spray (Noctiva – Avadel) formulation
of desmopressin acetate for treatment of nocturia due to
nocturnal polyuria in adults who wake up ≥2 times per
night to void. Nocdurna and Noctiva are the first two
products to be approved in the US for this indication.
Higher-strength nasal spray and oral tablet formulations
of desmopressin (DDAVP, and others) have been available
for years for treatment of diabetes insipidus and primary
nocturnal enuresis (bedwetting in children). In 2007, the
indication for primary...
Adapalene-Benzoyl Peroxide (Epiduo) for Acne
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009 (Issue 1310)
Epiduo gel (Galderma), a fixed-dose combination of
adapalene 0.1% (Differin), a synthetic retinoid ...
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin), a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.
Genvoya - A New 4-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016 (Issue 1488)
recommend that antiretroviral-naive
patients infected with HIV-1 receive an INSTIbased
regimen ...
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first
approval for tenofovir alafenamide (TAF), a tenofovir
prodrug. Stribild, a fixed-dose combination of
elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate (TDF), was approved in 2012.
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/
fluticasone ...
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics), for
treatment of seasonal allergic rhinitis symptoms
in persons ≥12 years old. Ryaltris is the second
intranasal antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which
is approved for use in persons ≥6 years old, was the
first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 doi:10.58347/tml.2023.1668c | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
Ozanimod (Zeposia) for Ulcerative Colitis
The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
. A
Drug class H
1
-antihistamine
Formulation 5-mg tablets
Route Oral
Tmax 1 hour
Metabolism Minimal ...
Levocetirizine (Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H1-antihistamine cetirizine (Zyrtec), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Sitagliptin (Januvia) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 01, 2007 (Issue 1251)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
1
The Medical ...
Sitagliptin phosphate (Januvia - Merck) is the first dipeptidyl-peptidase-4 (DPP-4) inhibitor to be marketed for treatment of type 2 diabetes. It has been approved by the FDA for oral use as monotherapy or in combination with metformin (Glucophage, and others), pioglitazone (Actos) or rosiglitazone (Avandia).
In Brief: Testosterone and Cardiovascular Risk
The Medical Letter on Drugs and Therapeutics • Mar 03, 2014 (Issue 1437)
, heart attack, and death in men taking FDA-approved
testosterone products.1
The first study examined ...
...
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
STANDARD TREATMENT — Drugs ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction